The phase I clinical trial of oral KOS-1022 will evaluate the safety, pharmacokinetics, pharmacodynamics, and bioavailability of escalating doses of the drug in patients with advanced solid tumors, as well as assess any preliminary evidence of antitumor activity.
The clinical trial will be conducted at the University of Colorado Health Science Center and the Presbyterian Hospital Medical Center at the University of Pennsylvania.
“Initiation of clinical testing of an oral formulation of KOS-1022 complements the development program for intravenous KOS-1022 and is an important step in our Hsp90 inhibitor program,” said Dr Daniel Santi, Kosan chairman and CEO.
Intravenous KOS-1022 is currently being evaluated in a phase I clinical trial in patients with hematologic malignancies as well as multiple phase I clinical studies in patients with advanced solid tumors.